PureTech Health (PRTC)
NASDAQ:PRTC
Want to see PRTC full AI Analyst Report?
PRTC Stock Chart & Stats
$17.58
-$0.90(-4.78%)
At close: 4:00 PM EST
$17.58
-$0.90(-4.78%)
Day’s Range― - ―
52-Week Range$14.50 - $19.99
Previous CloseN/A
Volume2.03K
Average Volume (3M)4.02K
Market Cap
$422.61M
Enterprise Value$183.86M
Total Cash (Recent Filing)$278.89M
Total Debt (Recent Filing)$19.76M
Price to Earnings (P/E)―
Beta0.42
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.69
Shares Outstanding24,341,820
10 Day Avg. Volume1,390
30 Day Avg. Volume4,023
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)1.34
Price to Sales (P/S)90.33
P/FCF Ratio-4.97
Enterprise Value/Market Cap0.44
Enterprise Value/Revenue39.55
Enterprise Value/Gross Profit-7.98
Enterprise Value/Ebitda-1.93
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-6.47
Revenue Forecast (FY)$49.50M
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe initiation of Phase 3 for LYT-100 is expected to drive value to Puretech Health Plc over the longer term.
Drug DevelopmentThe positive Phase 2b ELEVATE data supports moving ahead to Phase 3, showing a greater benefit on FVC compared to pirfenidone with a similar safety profile.
Strategic InitiativesPRTC announced the launch of a new private company, Celea Therapeutics, which will comprise the LYT-100 (deupirfenidone) program.
Bears Say
Financial StrategyNo financing was announced in conjunction with the NewCo, though it is expected to be a subsequent step.
PureTech Health News
PRTC FAQ
What was PureTech Health’s price range in the past 12 months?
PureTech Health lowest stock price was $14.50 and its highest was $19.99 in the past 12 months.
What is PureTech Health’s market cap?
PureTech Health’s market cap is $422.61M.
When is PureTech Health’s upcoming earnings report date?
PureTech Health’s upcoming earnings report date is Aug 27, 2026 which is in 118 days.
How were PureTech Health’s earnings last quarter?
PureTech Health released its earnings results on Apr 29, 2026. The company reported -$2.689 earnings per share for the quarter, missing the consensus estimate of -$1.94 by -$0.749.
Is PureTech Health overvalued?
According to Wall Street analysts PureTech Health’s price is currently Overvalued.
Does PureTech Health pay dividends?
PureTech Health does not currently pay dividends.
What is PureTech Health’s EPS estimate?
PureTech Health’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does PureTech Health have?
PureTech Health has 24,341,820 shares outstanding.
What happened to PureTech Health’s price movement after its last earnings report?
PureTech Health reported an EPS of -$2.689 in its last earnings report, missing expectations of -$1.94. Following the earnings report the stock price went down -4.079%.
Which hedge fund is a major shareholder of PureTech Health?
Currently, no hedge funds are holding shares in PRTC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
PureTech Health Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Company Description
PureTech Health
PureTech Health plc, a clinical-stage biotherapeutics company, discovers, develops, and commercializes medicines for inflammatory, fibrotic and immunological, intractable cancers, lymphatic and gastrointestinal, neurological and neuropsychological, and other diseases in the United States. The company offers KarXT targeting muscarinic acetylcholine receptors to treat schizophrenia and psychosis in Alzheimer's disease; a regenerative biology platform for androgenetic alopecia, epithelial ageing, and other medical conditions; an immunomodulation platform to treat chronic and acute inflammatory disorders; oral therapies based on defined consortia of bacteria is isolated from the human microbiome; and therapies to treat cognitive dysfunction associated with depression, multiple sclerosis, post COVID and ICU, and cancer related conditions. It also provides hematopoietic stem cell based therapies for patients with blood cancer; a voice-based technology platform to detect voice changes linked to health conditions; and a technology platform for the oral delivery of biologics, vaccines, and other drugs. In addition, the company is developing LYT-100 to treat lymphedema, and other lymphatic flow disorders; LYT-200, a IgG4 monoclonal antibody to target galectin-9; LYT-210 to treat solid tumors; Glyph, a synthetic lymphatic targeting chemistry platform; Orasome technology to enable the oral administration of macromolecule therapeutic payloads; meningeal lymphatics platform to treat Alzheimer's and Parkinson's diseases; and Alivio technology platform for inflammation-targeted disease immunomodulation. PureTech Health plc has collaboration and license agreements with Boehringer Ingelheim International GMBH; Eli Lilly and Company; Imbrium Therapeutics L.P.; and Shionogi & Co., Ltd. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.
PRTC Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call balanced meaningful clinical and operational progress with financial conservatism and some near‑term funding dependencies. Highlights include positive Phase Ib data for Gallop (LYT‑200) with dose selection and excellent safety, Celea’s Phase III readiness and substantial fundraising progress, a conservative cash runway to end‑2028, reduced operating loss (~27.6% improvement), continued monetization track record (>$1B historically and ~$125M realized from a royalty sale), and Seaport IPO activity — all indicating execution of the hub‑and‑spoke model. Lowlights are the year‑over‑year decline in cash (≈24.4% from 2024 to 2025 and further to ~$248M by March 31, 2026), a swing to consolidated net loss in 2025 driven by the absence of a prior one‑time gain, very low and flat revenues (~$4.7M), and reliance on external fundraising for key Phase III/registration programs which introduces execution and dilution risk. Overall, the positives around portfolio clinical progress, disciplined cost reduction and clear funding plans for key programs outweigh the financial headwinds, though the company remains dependent on successful external financings and monetizations to realize upside.View all PRTC earnings summariesTechnical Analysis
Ownership Overview
―
Insiders
<0.01% Mutual Funds
0.33% Other Institutional Investors
99.67% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---